Pharmaceutical sector: suspected anti-competitive agreements

The CMA is investigating alleged anti-competitive agreements in the pharmaceutical sector under Chapter I CA98 and Article 101 TFEU.

Case timetable

Date Action
October 2017 to June 2018 Initial investigation and information gathering. CMA analysis and review of information gathered.
October 2017 Investigation opened

Change log

The following changes have been made to the case timetable since it was first published in October 2017:

Date of change Reason for change Change made to timetable
19 April 2018 Additional time needed to gather and analyse additional information Date for completing initial investigation and information gathering changed from April 2018 to June 2018

Case information

On 10 October 2017, the CMA launched an investigation under Chapter I of the CA98 and Article 101 of the TFEU into suspected breaches of competition law by various parties. The investigation relates to alleged anti-competitive agreements and/or concerted practices in relation to generic pharmaceutical products.

The CMA has not reached a view on whether there is sufficient evidence of an infringement of competition law for it to issue a statement of objections to the parties under investigation. Not all cases result in the CMA issuing a statement of objections.


Assistant Project Directors

Maria Rican-Sevitz (020 3738 6859,

Nicholas Scola (020 3738 6931,

Project Director

Geoff Steadman (020 3738 6311,

Senior Responsible Officer

Ann Pope (020 3738 6786,

Published 13 October 2017
Last updated 19 April 2018 + show all updates
  1. Case timetable updated.
  2. First published.